Outcomes of salvage high dose-rate brachytherapy with or without pelvic external beam radiotherapy in patients with palpable local recurrence of prostate cancer after radical prostatectomy
Brachytherapy · 2023
DOI: 10.1016/j.brachy.2022.12.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2023. Verfasst von Lisa Ni und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of California San Francisco, Department of Radiation Oncology, San Francisco, CA. Hauptthemen laut MEDLINE: Brachytherapy, Prostatic Neoplasms, Urinary Incontinence. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Boston Scientific Corporation.
Abstract (Originalsprache)
PURPOSE: This study aims to evaluate the outcomes and toxicities in patients with palpable local recurrence of prostate cancer after radical prostatectomy (RP), who were treated with salvage high dose-rate brachytherapy (HDR-BT) with or without pelvic external beam radiotherapy (EBRT). METHODS: This retrospective review included patients with palpable local recurrence of prostate cancer after RP who underwent salvage HDR-BT at a single institution between 2002 and 2020. HDR-BT regimens included 950 cGy x 2 (N = 4) or 1500 cGy x 1 (N = 2) combined with EBRT; or monotherapy with 950 cGy x 4 (N = 1) or 800 cGy x 2 (N = 1). Toxicity was graded according to CTCAE Version 5.0. RESULTS: A total of 8 patients were included. Median follow-up was 49 months (range: 9-223 months). Median age at time of salvage brachytherapy was 68 years (range: 59-85 years). Seven out of 8 patients were alive at last follow-up. There have been no locoregional recurrences. Three patients developed distant metastatic disease. One patient developed acute grade 3 urinary obstruction requiring catheterization, which lasted for 1 day postbrachytherapy. One patient developed late grade 3 urinary incontinence 18 months after brachytherapy. There were no other grade 2+ toxicities. CONCLUSIONS: This study demonstrates the safety and efficacy of salvage HDR-BT in the setting of palpable local recurrence of prostate cancer after RP, with durable locoregional control and acceptable rates of toxicity. HDR-BT should be further explored as an option for dose-escalated salvage radiotherapy after prior radical prostatectomy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of California San Francisco, Department of Radiation Oncology, San Francisco, CA.
- University of California San Francisco, Department of Radiation Oncology, San Francisco, CA. Electronic address: ichow.hsu@ucsf.edu.
Förderung
- Boston Scientific Corporation
Zitieren
APA
Ni, L., Chen, K., Phuong, C., Sabbagh, A. R., Wong, A. C., Mohamad, O., & Hsu, I. C. (2023). Outcomes of salvage high dose-rate brachytherapy with or without pelvic external beam radiotherapy in patients with palpable local recurrence of prostate cancer after radical prostatectomy. Brachytherapy. https://doi.org/10.1016/j.brachy.2022.12.002
Vancouver
Ni L, Chen K, Phuong C, Sabbagh AR, Wong AC, Mohamad O, et al. Outcomes of salvage high dose-rate brachytherapy with or without pelvic external beam radiotherapy in patients with palpable local recurrence of prostate cancer after radical prostatectomy. Brachytherapy. 2023. doi:10.1016/j.brachy.2022.12.002
BibTeX
@article{Ni2023,
author = {Ni, Lisa and Chen, Katherine and Phuong, Christina and Sabbagh, Ali R and Wong, Anthony C and Mohamad, Osama and Hsu, I-Chow},
title = {Outcomes of salvage high dose-rate brachytherapy with or without pelvic external beam radiotherapy in patients with palpable local recurrence of prostate cancer after radical prostatectomy},
journal = {Brachytherapy},
year = {2023},
doi = {10.1016/j.brachy.2022.12.002}
}
EUVIMED